专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08541543B2 Peptides specific for hepatocellular carcinoma cells and applications thereof 有权
公开(公告)号：US08541543B2
公开(公告)日：2013-09-24
申请号：US12292401
申请日：2008-11-18
申请人： Han-Chung Wu , Chin-Tarng Lin , Albert Lo
发明人： Han-Chung Wu , Chin-Tarng Lin , Albert Lo
IPC分类号： C07K5/00
CPC分类号： G01N33/57438 , A61K38/00 , C07K7/08
摘要： Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. Novel treatment strategies derived from increased knowledge of molecular oncology are constantly being developed to cure this disease. Here, we used phage display to identify novel peptides, including (SP94), which binds specifically to HCC cells. In vitro, the phage clone PC94 binds to HCC cell lines. In vivo, PC94 homed specifically to tumor tissues but not to normal visceral organs in SCID mice bearing human HCC xenografts. The homing ability could be competitively inhibited by synthetic peptide, SP94. PC94 localized to tumor tissues but could not be detected in SP94-competed tumor tissues or in normal organs. In addition, PC94 recognized the tumor tissue but not non-tumor tissue in surgical specimens from HCC patients, with a positive rate of 61.3% (19/31). With the conjugation of SP94 and liposomal doxorubicin, a targeted drug delivery system enhanced the therapeutic efficacy against HCC xenografts through enhanced tumor apoptosis and decreased tumor angiogenesis. Our results indicate that SP94 can improve the systemic treatment of patients with advanced HCC.

2. 发明申请

US20050026860A1 Nucleolin antisense sequence for inhibition of cancer cell proliferation 审中-公开
标题翻译：用于抑制癌细胞增殖的核仁反义序列
公开(公告)号：US20050026860A1
公开(公告)日：2005-02-03
申请号：US10797822
申请日：2004-03-09
申请人： Chin-Tarng Lin , Han-Chung Wu
发明人： Chin-Tarng Lin , Han-Chung Wu
IPC分类号： A61K38/00 , A61K48/00 , C12N15/113 , C07H21/02 , C12Q1/68
CPC分类号： C12N15/113 , A61K38/00 , A61K48/00 , C12N2310/11 , C12N2310/315
摘要： Disclosed is a nucleolin antisense oligonucleotide for inhibition of tumor cell proliferation. The nucleolin antisense oligonucleotide comprising 20 nucleotides is complementary to the nucleolin mRNA. When the nucleolin antisense oligonucleotide hybridizes to nucleolin mRNA, it is effective in suppression of nucleolin RNA synthesis and the corresponding protein expression, which subsequently arrests the growth rate of tumor cells. The nucleolin antisense oligonucleotide is effective in inhibition of nucleolin expression of tumor cells in vitro and in vivo. Therefore, the nucleolin antisense oligonucleotide can be used as a therapeutic agent for inhibition of tumor cell proliferation.
摘要翻译：公开了用于抑制肿瘤细胞增殖的核仁核苷酸反义寡核苷酸。包含20个核苷酸的核仁核苷酸反义寡核苷酸与核仁素mRNA互补。当核仁核苷酸反义寡核苷酸与核仁蛋白mRNA杂交时，它有效抑制核仁核糖核酸合成和相应的蛋白质表达，从而阻止肿瘤细胞的生长速度。核仁核反义寡核苷酸在体外和体内有效抑制肿瘤细胞的核仁素表达。因此，核仁酰反义寡核苷酸可以用作抑制肿瘤细胞增殖的治疗剂。

3. 发明申请

US20090054363A1 Genetic markers and methods for detecting and treating cancers 有权
标题翻译：用于检测和治疗癌症的遗传标记和方法
公开(公告)号：US20090054363A1
公开(公告)日：2009-02-26
申请号：US11907697
申请日：2007-10-16
申请人： Chin-Tarng Lin , Han-Chung Wu , Dah-Yeou Huang
发明人： Chin-Tarng Lin , Han-Chung Wu , Dah-Yeou Huang
IPC分类号： A61K31/70 , A61P35/00 , C12Q1/68
CPC分类号： C12Q1/6886 , C12Q2600/118 , C12Q2600/158
摘要： The present invention provides genetic markers, SOX5 and SPARC, for distant metastasis and poor prognosis of detection of the high risk potential for cancer patients. In addition, the present invention also provides a method to predict the risk potential for cancer patients with distant metastasis and poor prognosis. This method comprises obtaining a tissue sample from a patient, evaluating the expression levels of the SOX5 and/or SPARC genetic markers in the sample; and comparing the expression levels of genetic markers with those of non-cancerous tissues. The patient is determined to have the high risk of distant metastasis or poor prognosis when the expression level of SOX5 is higher, or when the expression level of SPARC is lower, than that of non-cancerous tissue. Furthermore, the identified genetic marker SOX5 and/or SPARC can also be used for cancer targeted therapy, because down regulation of SOX5 and/or up regulation of SPARC expression in NOD-SCID can retard tumor growth and inhibit cell proliferation, migration, invasion and metastasis.
摘要翻译：本发明提供用于远处转移的遗传标记物SOX5和SPARC，并且对癌症患者的高潜力检测的预后差。此外，本发明还提供了一种预测远端转移癌症患者和预后不良的潜在风险的方法。该方法包括从患者获得组织样本，评估样品中SOX5和/或SPARC遗传标记的表达水平; 并比较遗传标记的表达水平与非癌组织的表达水平。当SOX5的表达水平较高时，或者当SPARC的表达水平低于非癌组织的表达水平时，患者被确定为具有远处转移的高风险或不良预后。此外，所鉴定的遗传标记SOX5和/或SPARC也可用于癌症靶向治疗，因为SOX5的下调和/或NOD-SCID中SPARC表达的上调可以延缓肿瘤生长并抑制细胞增殖，迁移，侵袭和转移。

4. 发明申请

US20090136418A1 Peptides specific for hepatocellular carcinoma cells and applications thereof 有权
标题翻译：特异于肝细胞癌细胞的肽及其应用
公开(公告)号：US20090136418A1
公开(公告)日：2009-05-28
申请号：US12292401
申请日：2008-11-18
申请人： Han-Chung Wu , Chin-Tarng Lin , Albert Lo
发明人： Han-Chung Wu , Chin-Tarng Lin , Albert Lo
IPC分类号： A61K51/00 , C12N15/11 , C07K7/00 , C07K16/18 , G01N33/574 , A61K9/127 , A61K38/10
CPC分类号： G01N33/57438 , A61K38/00 , C07K7/08
摘要： Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. Novel treatment strategies derived from increased knowledge of molecular oncology are constantly being developed to cure this disease. Here, we used phage display to identify novel peptides, including (SP94), which binds specifically to HCC cells. In vitro, the phage clone PC94 binds to HCC cell lines. In vivo, PC94 homed specifically to tumor tissues but not to normal visceral organs in SCID mice bearing human HCC xenografts. The homing ability could be competitively inhibited by synthetic peptide, SP94. PC94 localized to tumor tissues but could not be detected in SP94-competed tumor tissues or in normal organs. In addition, PC94 recognized the tumor tissue but not non-tumor tissue in surgical specimens from HCC patients, with a positive rate of 61.3% (19/31). With the conjugation of SP94 and liposomal doxorubicin, a targeted drug delivery system enhanced the therapeutic efficacy against HCC xenografts through enhanced tumor apoptosis and decreased tumor angiogenesis. Our results indicate that SP94 can improve the systemic treatment of patients with advanced HCC.
摘要翻译：肝细胞癌（HCC）是全球第四大癌症死亡原因。不断开发从增加分子肿瘤学知识得出的新型治疗策略来治愈这种疾病。在这里，我们使用噬菌体展示来鉴定新型肽，包括特异性结合HCC细胞的（SP94）。在体外，噬菌体克隆PC94结合HCC细胞系。在体内，PC94特异性地归巢于肿瘤组织，而不是携带人类HCC异种移植物的SCID小鼠中的正常内脏器官。归巢能力可以被合成肽SP94竞争性抑制。 PC94定位于肿瘤组织，但在SP94竞争的肿瘤组织或正常器官中不能检测到。此外，PC94在HCC患者手术标本中识别肿瘤组织，但不识别非肿瘤组织，阳性率为61.3％（19/31）。通过SP94和脂质体多柔比星的缀合，靶向药物递送系统通过增强肿瘤细胞凋亡和减少肿瘤血管生成来增强对HCC异种移植物的治疗效果。我们的研究结果表明，SP94可以改善晚期HCC患者的全身治疗。

5. 发明申请

US20080220409A1 Antigen of Dengue Virus Type 1 审中-公开
标题翻译：登革热病毒1型抗原
公开(公告)号：US20080220409A1
公开(公告)日：2008-09-11
申请号：US11683817
申请日：2007-03-08
申请人： Han-Chung Wu , Chin-Tarng Lin , Yun-Ching Chen
发明人： Han-Chung Wu , Chin-Tarng Lin , Yun-Ching Chen
IPC分类号： C12Q1/70 , C07K7/08 , C12N7/00
CPC分类号： C07K14/005 , C07K7/08 , C12N2770/24122 , G01N33/56983 , G01N2333/18 , Y02A50/53
摘要： Antigens and B-cell epitopes derived from dengue virus type 1 are provided. The antigens are specifically immunoreactive with sera from individuals infected with dengue virus type 1 but not reactive with sera from healthy individuals and individuals infected with dengue virus type 2. The antigens and epitopes are useful for development of diagnostic kits and reagents, and are useful tools as well in determining whether an individual is infected with dengue virus type 1, and for distinguishing infection from dengue virus type 2.
摘要翻译：提供了源自1型登革病毒的抗原和B细胞表位。抗原与来自感染1型登革热病毒的个体的血清特异性免疫反应，但与来自健康个体和感染了2型登革热病毒的个体的血清无反应。抗原和表位可用于开发诊断试剂盒和试剂，并且是有用的工具以及确定个体是否感染1型登革热病毒，以及区分2型登革热病毒的感染。

6. 发明申请

US20080193510A1 Peptides that target to tumor blood vessels of lung cancer and applications thereof 有权
标题翻译：靶向肺癌肿瘤血管的肽及其应用
公开(公告)号：US20080193510A1
公开(公告)日：2008-08-14
申请号：US11783926
申请日：2007-04-13
申请人： Han-Chung Wu , Chin-Tarng Lin , Tong-Young Lee , Szu-Yao Kuo
发明人： Han-Chung Wu , Chin-Tarng Lin , Tong-Young Lee , Szu-Yao Kuo
IPC分类号： G01N33/53 , A61K31/704 , A61K31/7088 , A61K38/10 , A61K9/127 , A61P35/00 , C07H21/00 , C07K14/00 , C07K16/00 , C07K7/08 , C12N1/00 , C12N15/63 , C12Q1/68
CPC分类号： A61K9/1271 , A61K47/62 , A61K47/6911 , G01N33/5082 , G01N33/57423
摘要： The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target neovasculature and were identified by in vivo phage display. One such peptide, SP5-52, recognized the neovasculature of multiple tumors in SCID mice, but did not target normal blood vessels. This peptide also binds to blood vessels of human lung cancer biopsy specimens. Liposomes comprising SP5-52 and doxorubicin enhanced the efficacy of the drug against multiple human cancer xenografts in SCID mice.
摘要翻译：本发明提供用于包括诊断和治疗在内的应用的核酸，肽和抗体。该肽靶向新血管生成，并通过体内噬菌体展示鉴定。一种这样的肽SP5-52在SCID小鼠中识别出多个肿瘤的新血管，但不能靶向正常的血管。该肽还结合人肺癌活检标本的血管。包含SP5-52和多柔比星的脂质体增强了药物对SCID小鼠中多种人类癌症异种移植物的功效。

7. 发明申请

US20080193375A1 Lung cancer-targeted peptides and applications thereof 有权
标题翻译：肺癌靶向肽及其应用
公开(公告)号：US20080193375A1
公开(公告)日：2008-08-14
申请号：US11783927
申请日：2007-04-13
申请人： Han-Chung Wu , Chin-Tarng Lin , De-Kuan Chang
发明人： Han-Chung Wu , Chin-Tarng Lin , De-Kuan Chang
IPC分类号： A61K9/00 , A61K38/10 , A61P35/00 , C07K16/00 , C07K7/08 , C12N15/63 , G01N33/574 , C12N1/00 , C07K2/00 , C07H21/00 , A61K51/12
CPC分类号： G01N33/57423 , A61K9/1271 , A61K47/62 , A61K47/6911 , A61K51/1234 , C07K7/08
摘要： The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target lung cancer and were identified by phage display. Targeting phage PC5-2 and synthetic peptide SP5-2 were both able to recognize human pulmonary tumor specimens from lung cancer patients. In SCID mice bearing NSCLC xenografts, the targeting phage was able to target tumor masses specifically. When the peptide was coupled to liposomes containing the anti-cancer drugs vinorelbine or doxorubicin, the efficacy of these drugs against human lung cancer xenografts was improved, the survival rate increased, and the drug toxicity was reduced.
摘要翻译：本发明提供用于包括诊断和治疗在内的应用的核酸，肽和抗体。这些肽靶向肺癌，并通过噬菌体展示鉴定。靶向噬菌体PC5-2和合成肽SP5-2均能够识别来自肺癌患者的人肺肿瘤标本。在携带NSCLC异种移植物的SCID小鼠中，靶向噬菌体能够特异性靶向肿瘤块。当肽与含有抗癌药物长春瑞滨或多柔比星的脂质体偶联时，这些药物对人肺癌异种移植物的疗效提高，存活率提高，药物毒性降低。

8. 发明申请

US20050010036A1 Peptide marker targeting to nasopharyngeal carcinoma cell and application thereof 有权
标题翻译：靶向鼻咽癌细胞的肽标记及其应用
公开(公告)号：US20050010036A1
公开(公告)日：2005-01-13
申请号：US10796892
申请日：2004-03-09
申请人： Han-Chung Wu , Chin-Tarng Lin , Tong-Young Lee
发明人： Han-Chung Wu , Chin-Tarng Lin , Tong-Young Lee
IPC分类号： A61K9/127 , A61K39/395 , C07K16/46
CPC分类号： A61K9/1271 , A61K38/00 , A61K47/64 , C07K5/0808 , C07K7/08
摘要： The present invention provides a peptide marker targeting to nasopharyngeal carcinoma (NPC) cells and application thereof. The peptide binds specifically to the cell surface of NPC cells. After conjugated with liposome containing chemotherapeutic drugs, such peptides deliver chemotherapeutic drugs to the tumor cells specifically and destruct tumor cells without damaging normal tissues and organs. Furthermore, such peptide is applied as a detector in the development of NPC diagnosis kit.
摘要翻译：本发明提供靶向鼻咽癌（NPC）细胞的肽标记及其应用。肽特异性结合NPC细胞的细胞表面。在与含有脂质体的化学治疗药物缀合之后，这些肽特异性地向肿瘤细胞递送化学治疗药物并破坏肿瘤细胞而不损害正常的组织和器官。此外，这种肽作为NPC诊断试剂盒开发中的检测器使用。

9. 发明授权

US08415453B2 Lung cancer-targeted peptides and applications thereof 有权
标题翻译：肺癌靶向肽及其应用
公开(公告)号：US08415453B2
公开(公告)日：2013-04-09
申请号：US11783927
申请日：2007-04-13
申请人： Han-Chung Wu , Chin-Tarng Lin , De-Kuan Chang
发明人： Han-Chung Wu , Chin-Tarng Lin , De-Kuan Chang
IPC分类号： A61K38/04 , A61K9/127 , A61P35/00
CPC分类号： G01N33/57423 , A61K9/1271 , A61K47/62 , A61K47/6911 , A61K51/1234 , C07K7/08
摘要： The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target lung cancer and were identified by phage display. Targeting phage PC5-2 and synthetic peptide SP5-2 were both able to recognize human pulmonary tumor specimens from lung cancer patients. In SCID mice bearing NSCLC xenografts, the targeting phage was able to target tumor masses specifically. When the peptide was coupled to liposomes containing the anti-cancer drugs vinorelbine or doxorubicin, the efficacy of these drugs against human lung cancer xenografts was improved, the survival rate increased, and the drug toxicity was reduced.
摘要翻译：本发明提供用于包括诊断和治疗在内的应用的核酸，肽和抗体。这些肽靶向肺癌，并通过噬菌体展示鉴定。靶向噬菌体PC5-2和合成肽SP5-2均能够识别来自肺癌患者的人肺肿瘤标本。在携带NSCLC异种移植物的SCID小鼠中，靶向噬菌体能够特异性地靶向肿瘤块。当肽与含有抗癌药物长春瑞滨或多柔比星的脂质体偶联时，这些药物对人肺癌异种移植物的疗效提高，存活率提高，药物毒性降低。

10. 发明授权

US08088887B2 Peptide-conjugates that bind to VEGF-stimulated or tumor vasculature and methods of treatment 有权
标题翻译：结合VEGF刺激或肿瘤脉管系统的肽缀合物和治疗方法
公开(公告)号：US08088887B2
公开(公告)日：2012-01-03
申请号：US11783926
申请日：2007-04-13
申请人： Han-Chung Wu , Chin-Tarng Lin , Tong-Young Lee , Szu-Yao Kuo
发明人： Han-Chung Wu , Chin-Tarng Lin , Tong-Young Lee , Szu-Yao Kuo
IPC分类号： A61K38/00 , A61K38/18 , C07K2/00 , C07K4/00 , C07K5/00 , C07K7/00 , C07K14/00 , C07K16/00 , C07K17/00 , C07K14/515 , A61P35/00
CPC分类号： A61K9/1271 , A61K47/62 , A61K47/6911 , G01N33/5082 , G01N33/57423
摘要： The invention provides nucleic acids, peptides, and antibodies for use in applications including diagnosis and therapy. The peptides target neovasculature and were identified by in vivo phage display. One such peptide, SP5-52, recognized the neovasculature of multiple tumors in SCID mice, but did not target normal blood vessels. This peptide also binds to blood vessels of human lung cancer biopsy specimens. Liposomes comprising SP5-52 and doxorubicin enhanced the efficacy of the drug against multiple human cancer xenografts in SCID mice.
摘要翻译：本发明提供用于包括诊断和治疗在内的应用的核酸，肽和抗体。该肽靶向新血管生成，并通过体内噬菌体展示鉴定。一种这样的肽SP5-52在SCID小鼠中识别出多个肿瘤的新血管，但不能靶向正常的血管。该肽还结合人肺癌活检标本的血管。包含SP5-52和多柔比星的脂质体增强了药物对SCID小鼠中多种人类癌症异种移植物的功效。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式